What’s Next for Biopharma Under the Inflation Reduction Act

As the one-year anniversary of the IRA being signed into law approaches, questions remain about how the new law will reverberate changes across the biopharma industry. the changes brought by the IRA—headlined by the Medicare Drug Price Negotiation Program and Medicare Part D prescription drug plan reforms—will introduce new considerations and challenges for biopharma companies.

The biopharma companies and their partners should prioritize planning now to ensure they understand the law’s provisions and how it will affect their portfolios, including market access engagement, pricing strategies, and patient assistance programs.